Diabetes - Perspectives in Drug Therapy (eBook, PDF)
Schade – dieser Artikel ist leider ausverkauft. Sobald wir wissen, ob und wann der Artikel wieder verfügbar ist, informieren wir Sie an dieser Stelle.
Diabetes - Perspectives in Drug Therapy (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The chapters of this book report cutting-edge research on molecular events in adiposity and type 2 diabetes, thus opening the way for innovative drug-based therapeutic strategies. It addresses all those who wish to keep in touch with recent developments in the field.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 5.88MB
- Upload möglich
The chapters of this book report cutting-edge research on molecular events in adiposity and type 2 diabetes, thus opening the way for innovative drug-based therapeutic strategies. It addresses all those who wish to keep in touch with recent developments in the field.
Produktdetails
- Produktdetails
- Verlag: Springer Berlin
- Erscheinungstermin: 11. April 2011
- Englisch
- ISBN-13: 9783642172144
- Artikelnr.: 37374151
- Verlag: Springer Berlin
- Erscheinungstermin: 11. April 2011
- Englisch
- ISBN-13: 9783642172144
- Artikelnr.: 37374151
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes. Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes . Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy . Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes. Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes . Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy . Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects